Dr. Eunice Wang & Dr.Andre Schuh
Dr. Andre Schuh – Princess Margaret Cancer Centre
Dr. Andre Schuh obtained his MD degree at the University of Toronto, Ontario, Canada, in 1983, and thereafter received subspecialty certification in Internal Medicine (1987) and Hematology (1988), followed by a four year Molecular Biology Fellowship. Dr. Schuh has been a staff physician at the University Health Network/Princess Margaret Cancer Centre, Toronto, Ontario, since 1992, where he has long focused on acute leukemia and MDS. He was the head of the leukemia program at Princess Margaret from 2010-2014, and from 2012-2018, was Medical Director, Malignant Hematology. His current interests include Acute Leukemia management and clinical trials (especially in the older patient), and the development of Canadian province- and country-wide leukemia management strategies.
Dr. Eunice Wang – Roswell Comprehensive Cancer Center
Dr. Eunice Wang is the Chief of the Leukemia Service and Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. She is also Medical Director of Chemotherapy/Infusion Services and Director of the Roswell Park Hematological Procurement Shared Resource. In addition, she has an appointment as an Associate Professor, Department of Medicine, Jacobs School of Medicine & Biomedical Sciences at the University of Buffalo (State University of New York). Dr. Wang earned her medical degree from the Keck School of Medicine, University of Southern California and completed residency training in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT. She completed a clinical hematology-oncology and research fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. Dr. Wang’s research focuses on translation of promising agents into therapies for acute leukemias (AML, ALL) and myeloid malignancies (MDS, MPN). She has authored/co-authored over 100 peer-reviewed articles, book chapters, and editorials and previously served on the National Comprehensive Cancer Network (NCCN) guideline panels for AML, ALL, and MPN for several years. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award (CCITLA) and a Mentored Research Scholar award from the American Cancer Society.